Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials
-
Xinchen Wang
,
Qi Wang
and
Shijian Quan
Abstract
Diabetic nephropathy (DN) is considered as one of the most popular microvascular complications of diabetes and the leading cause of death among diabetic patients. Currently, even though safflower yellow (SY) is widely adapted in the clinical treatment of DN, no meta-analysis can guarantee the safety of this treatment. This paper aims to evaluate the dominant method of SY on DN disease. The reliable source of information for randomized controlled trials (RCTs) and clinical research is listed as follows: the Chinese Biomedical Literature database, Chongqing VIP, Embase, the Cochrane Library and the China Academic Journals Full-text Database (CNKI). The CNKI search included Chinese journal articles, the full-text of important conferences and dissertations up to March 30, 2017. We picked out some particularly influential outcome variables including urinary albumin excretion rate (UAER), fasting blood sugar (FBG), blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) in each extracted study. In total, 1289 participants were included in this meta-analysis. The efficacy of SY alone or combined with Western medicine in the treatment of DN was better with statistically significant factors (odds ratio [OR] = 3.6, 95% confidence interval [CI] [2.37, 5.47], p < 0.00001). We found that SY lessened the UAER, heightened the proportion of blood sugar and beneficially improved other detective indicators related to DN. Therefore, SY used alone or in combination with Western medicine was significantly more efficacious with lower toxicity than Western medicine alone.
Acknowledgments
Thanks for the help provided by the fund of Guangdong Provincial Major Science, Technology for Special Program of China and Key R & D and extension projects in Henan Province (Scientific and Technological research, 192102310166), thanks to the comments and support provided by professors of the Institute of Clinical Pharmacology, Guangzhou University of Traditional Chinese Medicine, and the comments and hard work provided by the editors of your journal.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Research was funded by the Guangdong Provincial Major Science and Technology for Special Program of China No. 2012A080202017 and No. 2015A030302072.
Employment or leadership: None declared.
Honorarium: None declared.
Ethical statement: Primary data for humans nor for animals were not collected for this research work.
Declaration of conflict of interest: The authors declare no conflict of interest.
References
1. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995;44:489–94.10.2337/diab.44.5.489Search in Google Scholar
2. Yang XY, Ren YF. Research progress on pharmacological action of safflower yellow pigment. J Trop Med 2015;15:421–3.Search in Google Scholar
3. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686–90.10.2337/diacare.28.11.2686Search in Google Scholar
4. Liang S, Zhang XG, Cai GY, Zhu HY, Zhou JH. Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. PLoS One 2013;8:e64184.10.1371/journal.pone.0064184Search in Google Scholar
5. Chen KH, Chen YL, Tang HY, Hung CC, Yen TH. Dietary leucine supplement ameliorates hepatic steatosis and diabetic nephropathy in db/db mice. Int J Mol Sci 2018;19:1921.10.3390/ijms19071921Search in Google Scholar
6. Wang J, Li R, Deng Z. Xueshuantong for injection ameliorates diabetic nephropathy in a rat model of streptozotocin-induced diabetes. Chin J Physiol 2018;61:349–59.Search in Google Scholar
7. Huang WJ, Fu Q, Xiao YH, Gong Q, Wu WJ. Effect of Qufengtongluo decoction on PI3K/Akt signaling pathway in the kidney of type 2 diabetes mellitus rat (GK Rat) with diabetic nephropathy. Evid Based Complement Alternat Med 2018;2018:8421979.10.1155/2018/8421979Search in Google Scholar
8. Du YG, Zhang KN, Gao ZL, Dai F, Wu XX. Tangshen formula improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-kappaB pathway. Exp Ther Med 2018;15: 2156–64.Search in Google Scholar
9. Hotta N, Kawamori R, Fukuda M, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med 2012;29:1529–33.10.1111/j.1464-5491.2012.03684.xSearch in Google Scholar
10. Zhu HB, Zhang L, Wang Z. Therapeutic effects of hydroxy safflor yellow A on focal cerebralis chemic in jury in rats and its primary mechanisms. J Asian Nat Prod Res 2005;7:607–13.10.1080/10286020310001625120Search in Google Scholar
11. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34–44.10.1101/gad.14.1.34Search in Google Scholar
12. Lian ZQ, Zhao DL, Zhu HB. Hydroxy safflower yellow A upregulates the expression of hypoxia-inducible factor-1α in vascular endothelial cells under hypoxia. Acta Pharm Sinic 2008;5:484–9.Search in Google Scholar
13. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H. ROS and PDGF-beta receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 2009;297:C389–96.10.1152/ajpcell.00206.2009Search in Google Scholar
14. Zhao JS, Fang MX, Guo QY, Li YF, Xu BY. Hydroxy safflower yellow A inhibits PDGF-induced proliferation of rat vascular smooth muscle cells. Chin J Cell B 2015;6:827–31.Search in Google Scholar
15. Watanabe T, Terabe S. Analysis of natural food pigments by capillary electrophoresis. J Chromatogr 2000;880:311–22.10.1016/S0021-9673(00)00209-0Search in Google Scholar
16. Wang Y, Zhang C, Peng W, Xia Z, Gan P. Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury. Mol Med Rep 2016;14:3690–6.10.3892/mmr.2016.5720Search in Google Scholar
17. Fang YH, Zhang JP, Zhou SX, Zheng JF, Yu YW. The relationship between serum vascular hemophilia factor, platelet activation factor and diabetic nephropathy in type 2 diabetic patients. J Branch Campus the First Military Med Univ 2005;25:729–31.Search in Google Scholar
18. Tian L, Wu GR, Wang Y. Progress in the study of safflower yellow pigment. Northwest Pharm J 2007;22:218–20.Search in Google Scholar
19. Han SY, Kim CH, Kim HS, Jee YH, Song HK. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17:1362–72.10.1681/ASN.2005111196Search in Google Scholar
20. Huang MF, Guo L, Su XS, Jiao BN, Fu CM. Research progress of safflower yellow pigment journal. China Condiment 2008;6:24–8.Search in Google Scholar
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, W64.10.7326/0003-4819-151-4-200908180-00135Search in Google Scholar
22. Qian RL. New diagnostic criteria and classification of diabetes. Chin J Diabetes 2000;8:5–6.Search in Google Scholar
23. Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diabetes Metab Rev 1988;4:453–83.10.1002/dmr.5610040504Search in Google Scholar
24. Zheng XY. Clinical guideline of new drugs for traditional Chinese medicine. Chin Med Sci and Tech J 2002;1:139–43.Search in Google Scholar
25. Song BL, Jiang HW, Li LP, Fu LJ, Ma YJ. Therapeutic effect of safflor yellow injection and pancreatic kininogenase on early diabetic nephropathy. China Modern Doctor 2011;49: 141–2.Search in Google Scholar
26. Gao Y, Yuan LL, Zhang LM, Liu N. Analysis of 44 cases of early diabetic nephropathy treated by safflor yellow combined with telmisartan. Guizhou Med J 2015;39:986–7.Search in Google Scholar
27. Wang HQ, Wang GY, Wei JZ. Safflower yellow combined with pancreatic kallikrein treatment clinical observation of early diabetic nephropathy. Chin J Prim Med Pharm 2016;23:834–5.Search in Google Scholar
28. Fang ZF. Valsartan combined with safflower sodium in the treatment of diabetic nephropathy proteinuria clinical research. Asia-Pac Trad Med 2015;11:134–5.Search in Google Scholar
29. Gao Y, Yuan LL, Liu ZQ, Zhang LM, Li J. Application value of safflor yellow in early diabetic nephropathy. ShanXi Med J 2015;44:297–8.Search in Google Scholar
30. Xu TD, He CM. Therapeutic effect of safflor yellow injection and pancreatic kininogenase on early diabetic nephropathy. North Pharm J 2014;11:32–3.Search in Google Scholar
31. Li Z, Wang WL. Therapeutic effect of safflor yellow combined with losartan on early diabetic nephropathy. People Mil Surg 2012;S1:27–8.Search in Google Scholar
32. Bai XM, Li XD, Song H, Zhang XD, Li H. Safflower yellow impact on early diabetic nephropathy hs-CRP, IL-8. Chin J Integr Trad and West Neph 2012;8:698–9.Search in Google Scholar
33. Jiao SY, Zhang CF. Clinical observation of point injection of safflower yellow injection in treating early diabetic nephropathy. Chin Heal Ind 2012;11:81.Search in Google Scholar
34. Guo DZ, Wang YH, Chen ZQ, Bian D, Qi HC. Treatment of diabetic nephropathy by saffron yellow powder injection and benazepril: a clinical observation of 39 cases. Chin J Integr Trad West Med 2008;28:360–1.Search in Google Scholar
35. Gao Y, Yuan LL, Zheng P, Liu N, Bi Zy. Effect of safflor yellow combined with benazepril on renal function in patients with early diabetic nephropathy. Prog Mod BioMed 2015;8:4333–4.Search in Google Scholar
36. Xiao YX, Gu YF. Effects of safflor yellow on inflammatory reaction and proteinuria in patients with diabetic nephropathy. J Chengde Med Coll 2016;33:194–5.Search in Google Scholar
37. Shi ZM. Effects of valsartan combined with safflower yellow on diabetic nephropathy UAER and hs – CRP. Mod Diagn Treat 2015;26:3431–2.Search in Google Scholar
38. Qiu TL, Wang X, Yuan J, Wang G, Wang M. Clinical effects of injection of safflower yellow in the treatment of early diabetic nephropathy. Prog Mod BioMed 2013;13:5075–6.Search in Google Scholar
39. Yang XP, Dai LF. Protective effects of safflor yellow injection combined with α-lipoic acid on type 2 diabetic nephropathy. J Yunnan Univ Tradit Chin Med 2012;33:23–4.Search in Google Scholar
40. Zhang XY. Clinical efficacy of safflor yellow combined with irbesartan in the treatment of diabetic nephropathy. Prac Clin Med 2010;11:24–5.Search in Google Scholar
41. Yang LH, Yang GH. Clinical study of safflor yellow in treating type 2 diabetic nephropathy. Proce Clin Med 2010;19:502–3.Search in Google Scholar
42. Zhang MH. Early treatment of type 2 diabetic nephropathy with safflor yellow injection plus enalapril. J Guangzhou Univ Tradit Chin Med 2014;34:938–9.Search in Google Scholar
43. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.10.1016/0197-2456(95)00134-4Search in Google Scholar
44. Li XH, Dong ZH, Hui D. Study on the etiology and pathogenesis of diabetic nephropathy [J]. Shaanxi Med J 2015;26:552–3.Search in Google Scholar
45. Guo DZ, Wang YH, Bian D, Liu XR, Wang YK. Effects of safflower yellow onblood vessels of rats with diabetic nephropathy angiotensin system. Chin Trad Pate Med 2009;31:1832–6.Search in Google Scholar
46. Bai XM, Li XD, Song J, Zhang XD, Li H. Safflower yellow on hs-CRP and IL-8 in patients with early diabetic nephropathy. Chin J Integr Trad West Neph 2012;13:698–700.Search in Google Scholar
47. Fang YH, Zhang JP, Zhou SX, Zheng JF, Yu YW. Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy. Acad J Second Military Med Univ 2005;25:729–31.Search in Google Scholar
48. Tian L, Wu GR, Wang Y. Research progress of safflower yellow pigment. Northwest Pharm J 2007;4:218–20.Search in Google Scholar
49. Xi HS. Shenkang combined alprostadil delayed the clinical efficacy of chronic renal failure. Chin Health Care Nutrition 2013;23:1930.Search in Google Scholar
50. Guo CH, Yu XM. Nursing care of early stage of hemodialysis in patients with diabetic renal failure. Guide Chin Med 2013;35:217–8.Search in Google Scholar
51. Pang XL, Feng GW, Shang WJ, Liu L, Li JF. The effect of safflower yellow pigment on early renal function of kidney transplantation was observed. J Chin Pract Diag Thera 2014;28:298–300.Search in Google Scholar
52. Jiang H, Guo GB, Huang Y, Long YP, Dai ZY. Effect of safflor yellow injection on hemorrheology in bedridden patients. Chin J Clin Pharm 2015;31:450–2.Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials
- Original Articles
- Genomic study via chromosomal microarray analysis in a group of Romanian patients with obesity and developmental disability/intellectual disability
- Clinical and molecular characteristics and time of diagnosis of patients with classical galactosemia in an unscreened population in Turkey
- Assessment of retinal thickness as a marker of brain masculinization in children with congenital adrenal hyperplasia: a pilot study
- Auditory event-related potentials demonstrate early cognitive impairment in children with subclinical hypothyroidism
- Cardiovascular risk factors in children with type 1 diabetes mellitus
- The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents
- The metabolic consequences of overweight in a cohort of children with type 1 diabetes
- The spectrum of pediatric adrenal insufficiency: insights from 34 years of experience
- Growth screening in children aged 3–5 years: a useful tool for public health programs in community pediatrics
- Selective receptor-mediated impairment of growth factor activity in neonatal- and X-linked adrenoleukodystrophy patients
- Determinants for low bone mineral density in pre-school children: a matched case-control study in Wuhan, China
- Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents
- Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes
- Severe, persistent neonatal hypoglycemia as a presenting feature in patients with congenital hypopituitarism: a review of our case series
- Case Reports
- Short stature in a boy with atypical progeria syndrome due to LMNA c.433G>A [p.(Glu145Lys)]: apparent growth hormone deficiency but poor response to growth hormone therapy
- A novel mutation leading to the lethal form of carnitine palmitoyltransferase type-2 deficiency
- Diagnosis of cyclic Cushing’s disease manifests as early morning hyperglycemia in a patient with previously well-controlled type 1 diabetes
- Short Communication
- Replacement of breastfeeding with medical food for the treatment of galactosemia and phenylketonuria: maternal stress
Articles in the same Issue
- Frontmatter
- Review
- Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials
- Original Articles
- Genomic study via chromosomal microarray analysis in a group of Romanian patients with obesity and developmental disability/intellectual disability
- Clinical and molecular characteristics and time of diagnosis of patients with classical galactosemia in an unscreened population in Turkey
- Assessment of retinal thickness as a marker of brain masculinization in children with congenital adrenal hyperplasia: a pilot study
- Auditory event-related potentials demonstrate early cognitive impairment in children with subclinical hypothyroidism
- Cardiovascular risk factors in children with type 1 diabetes mellitus
- The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents
- The metabolic consequences of overweight in a cohort of children with type 1 diabetes
- The spectrum of pediatric adrenal insufficiency: insights from 34 years of experience
- Growth screening in children aged 3–5 years: a useful tool for public health programs in community pediatrics
- Selective receptor-mediated impairment of growth factor activity in neonatal- and X-linked adrenoleukodystrophy patients
- Determinants for low bone mineral density in pre-school children: a matched case-control study in Wuhan, China
- Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents
- Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes
- Severe, persistent neonatal hypoglycemia as a presenting feature in patients with congenital hypopituitarism: a review of our case series
- Case Reports
- Short stature in a boy with atypical progeria syndrome due to LMNA c.433G>A [p.(Glu145Lys)]: apparent growth hormone deficiency but poor response to growth hormone therapy
- A novel mutation leading to the lethal form of carnitine palmitoyltransferase type-2 deficiency
- Diagnosis of cyclic Cushing’s disease manifests as early morning hyperglycemia in a patient with previously well-controlled type 1 diabetes
- Short Communication
- Replacement of breastfeeding with medical food for the treatment of galactosemia and phenylketonuria: maternal stress
